A Phase 2 interventional study of MM36 topical ointment, 1% in Atopic Dermatitis, sponsored by Medimetriks Pharmaceuticals, Inc. Completed at 12 sites in 3 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Medimetriks Pharmaceuticals, Inc (part of Eurofarma Laboratorios S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 15th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 5th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2016.
This study's enrollment of 32 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Medimetriks Pharmaceuticals, Inc, one of the names counted as Eurofarma Laboratorios S.A.. Under that name alone:
This is the only study on the registry with Medimetriks Pharmaceuticals, Inc as lead sponsor.
Eurofarma Laboratorios S.A. has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.
This is a multi-center, open-label study to assess the degree of systemic exposure and safety of MM36 1% ointment following 4 weeks of twice daily dosing under maximal-use conditions in pediatric subjects with atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MM36 topical ointment, 1%, applied twice daily for 28 days
Drug: MM36 topical ointment, 1%
Twice daily application for 28 consecutive days
Also known as: OPA-15406
Maximum Observed Plasma Concentration (Cmax) of MM36
Maximum observed plasma concentration of MM36 on Day 1
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 1
Maximum Observed Plasma Concentration (Cmax) of MM36
Maximum observed plasma concentration of MM36 after two weeks of twice daily application (steady state)
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 15
Time of Maximum Observed Plasma Concentration (Tmax) of MM36
Time of Maximum Observed Plasma Concentration (Tmax) of MM36 on Day 1
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 1
Time of Maximum Observed Plasma Concentration (Tmax) of MM36
Time of Maximum Observed Plasma Concentration (Tmax) of MM36 on Day 15
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 15
Area Under the Plasma Concentration-Time Curve From Time Zero To the Time of Last Quantifiable Plasma Concentration of MM36
Area Under the Plasma Concentration-time Curve from Time Zero To the time of Last Quantifiable Plasma Concentration of MM36 on Day 1
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 1
Area Under the Plasma Concentration-Time Curve From Time Zero To the Time of Last Quantifiable Plasma Concentration of MM36
Area Under the Plasma Concentration-Time Curve From Time Zero To the time of Last Quantifiable Plasma Concentration of MM36 on Day 15
Time frame: Pre-dose (0 hour), 1, 4, and 8 hours post-dose on Day 15
Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: up to 4 weeks
Treatment-Emergent Adverse Events (AEs) According to Severity
Number of Participants With Treatment-Emergent Adverse Events (AEs) According to Severity. Adverse events were classified according to severity as: mild - an event that is usually transient in nature and generally not interfering with normal activities; moderate - an event that is sufficiently discomforting to interfere with normal activities; severe - an event that is incapacitating with inability to work or do usual activity or inability to work or perform normal daily activity.
Time frame: up to 4 weeks
Application Site Adverse Events (AEs)
Number of Participants With Application Site Adverse Events (AEs)
Time frame: up to 4 weeks
Application Site Adverse Events (AEs) According to Severity
Number of Participants With Application Site Adverse Events (AEs) According to Severity. Adverse events were classified according to severity as: mild - an event that is usually transient in nature and generally not interfering with normal activities; moderate - an event that is sufficiently discomforting to interfere with normal activities; severe - an event that is incapacitating with inability to work or do usual activity or inability to work or perform normal daily activity.
Time frame: up to 4 weeks
Clinically Meaningful Laboratory Test Median Changes From Baseline
Number of Participants With Clinically Meaningful Laboratory Test Median Changes From Baseline. Clinical meaningfulness of laboratory test changes was determined at the investigator's discretion.
Time frame: Day 29
Clinically Meaningful Vital Sign Median Changes From Baseline
Number of Participants With Clinically Meaningful Vital Sign Median Changes From Baseline. Clinical meaningfulness of vital sign changes was determined at the investigator's discretion.
Time frame: Day 29
Clinically Meaningful ECG Median Changes From Baseline to Day 15
Number of Participants With Clinically Meaningful ECG Median Changes from Baseline. Clinical meaningfulness of ECG changes was determined at the investigator's discretion.
Time frame: Day 15
Clinically Meaningful ECG Median Changes From Baseline to Day 29
Number of Participants With Clinically Meaningful ECG Median Changes from Baseline. Clinical meaningfulness of ECG changes was determined at the investigator's discretion.
Time frame: Day 29
| Milestone | MM36 Topical Ointment, 1% |
|---|---|
| Started | 32 |
| Completed | 28 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by parent/guardian | 3 |
Maximum observed plasma concentration of MM36 on Day 1
| ng/mL | MM36 Topical Ointment, 1% |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of MM36 | 23.1 ± 23.4 |
Maximum observed plasma concentration of MM36 after two weeks of twice daily application (steady state)
| ng/mL | MM36 Topical Ointment, 1% |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of MM36 | 16.9 ± 21.9 |
Time of Maximum Observed Plasma Concentration (Tmax) of MM36 on Day 1
| hours | MM36 Topical Ointment, 1% |
|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of MM36 | 4.22 ± 2.02 |
Time of Maximum Observed Plasma Concentration (Tmax) of MM36 on Day 15
| hours | MM36 Topical Ointment, 1% |
|---|---|
| Time of Maximum Observed Plasma Concentration (Tmax) of MM36 | 3.80 ± 2.24 |
Area Under the Plasma Concentration-time Curve from Time Zero To the time of Last Quantifiable Plasma Concentration of MM36 on Day 1
| ng·hr/mL | MM36 Topical Ointment, 1% |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero To the Time of Last Quantifiable Plasma Concentration of MM36 | 107 ± 94.1 |
Area Under the Plasma Concentration-Time Curve From Time Zero To the time of Last Quantifiable Plasma Concentration of MM36 on Day 15
| ng·hr/mL | MM36 Topical Ointment, 1% |
|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero To the Time of Last Quantifiable Plasma Concentration of MM36 | 86.2 ± 79.6 |
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
| participants | MM36 Topical Ointment, 1% |
|---|---|
| No AE | 24 |
| AE | 7 |
| SAE | 0 |
Number of Participants With Treatment-Emergent Adverse Events (AEs) According to Severity. Adverse events were classified according to severity as: mild - an event that is usually transient in nature and generally not interfering with normal activities; moderate - an event that is sufficiently discomforting to interfere with normal activities; severe - an event that is incapacitating with inability to work or do usual activity or inability to work or perform normal daily activity.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| None | 24 |
| Mild | 6 |
| Moderate | 1 |
| Severe | 0 |
Number of Participants With Application Site Adverse Events (AEs)
| participants | MM36 Topical Ointment, 1% |
|---|---|
| None | 29 |
| Application site pain | 1 |
| Application site rash | 1 |
Number of Participants With Application Site Adverse Events (AEs) According to Severity. Adverse events were classified according to severity as: mild - an event that is usually transient in nature and generally not interfering with normal activities; moderate - an event that is sufficiently discomforting to interfere with normal activities; severe - an event that is incapacitating with inability to work or do usual activity or inability to work or perform normal daily activity.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| None | 29 |
| Mild | 1 |
| Moderate | 1 |
| Severe | 0 |
Number of Participants With Clinically Meaningful Laboratory Test Median Changes From Baseline. Clinical meaningfulness of laboratory test changes was determined at the investigator's discretion.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| Clinically Meaningful Laboratory Test Median Changes From Baseline | 0 |
Number of Participants With Clinically Meaningful Vital Sign Median Changes From Baseline. Clinical meaningfulness of vital sign changes was determined at the investigator's discretion.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| Clinically Meaningful Vital Sign Median Changes From Baseline | 0 |
Number of Participants With Clinically Meaningful ECG Median Changes from Baseline. Clinical meaningfulness of ECG changes was determined at the investigator's discretion.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| Clinically Meaningful ECG Median Changes From Baseline to Day 15 | 0 |
Number of Participants With Clinically Meaningful ECG Median Changes from Baseline. Clinical meaningfulness of ECG changes was determined at the investigator's discretion.
| participants | MM36 Topical Ointment, 1% |
|---|---|
| Clinically Meaningful ECG Median Changes From Baseline to Day 29 | 0 |
Collected over up to 4 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MM36 Topical Ointment, 1% | 0/31 (0%) | 0/31 (0%) | 7/31 (22.6%) |
| Event | MM36 Topical Ointment, 1% |
|---|---|
| VomitingGastrointestinal disorders | 1/31 |
| Application site painGeneral disorders | 1/31 |
| Application site rashGeneral disorders | 1/31 |
| Influenza like illnessGeneral disorders | 1/31 |
| PyrexiaGeneral disorders | 1/31 |
| NasopharyngitisInfections and infestations | 1/31 |
| TonsillitisInfections and infestations | 1/31 |
| Upper respiratory tract infectionInfections and infestations | 1/31 |
| Eosinophil count increasedInvestigations | 1/31 |
| Age, Categorical(Participants) | MM36 Topical Ointment, 1% |
|---|---|
| <=18 years | 32 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | MM36 Topical Ointment, 1% |
|---|---|
| Mean | 7.9 ± 4.33 |
| Sex: Female, Male(Participants) | MM36 Topical Ointment, 1% |
|---|---|
| Female | 16 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | MM36 Topical Ointment, 1% |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | MM36 Topical Ointment, 1% |
|---|---|
| American Indian or Alaska Native | 2 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 17 |
| More than one race | 7 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | MM36 Topical Ointment, 1% |
|---|---|
| United States | 15 |
| Panama | 11 |
| Honduras | 6 |
| Percentage of Body Surface Area (BSA) Involved(%) | MM36 Topical Ointment, 1% |
|---|---|
| Mean | 43.7 ± 13.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Oct 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast